Regeneron Pharmaceuticals Inc (REGN) : J&p(china)capital Managementltd reduced its stake in Regeneron Pharmaceuticals Inc by 46.98% during the most recent quarter end. The investment management company now holds a total of 16,600 shares of Regeneron Pharmaceuticals Inc which is valued at $6,997,564 after selling 14,708 shares in Regeneron Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Regeneron Pharmaceuticals Inc makes up approximately 1.96% of J&p(china)capital Managementltd’s portfolio.
Other Hedge Funds, Including , Artal Group S.a. added REGN to its portfolio by purchasing 50,000 company shares during the most recent quarter which is valued at $21,077,000. Regeneron Pharmaceuticals Inc makes up approx 0.44% of Artal Group S.a.’s portfolio.Hutchens Investment Management Inc boosted its stake in REGN in the latest quarter, The investment management firm added 2,300 additional shares and now holds a total of 3,185 shares of Regeneron Pharmaceuticals Inc which is valued at $1,342,605. Regeneron Pharmaceuticals Inc makes up approx 1.24% of Hutchens Investment Management Inc’s portfolio.Blackrock Fund Advisors boosted its stake in REGN in the latest quarter, The investment management firm added 13,282 additional shares and now holds a total of 2,221,959 shares of Regeneron Pharmaceuticals Inc which is valued at $936,644,597. Regeneron Pharmaceuticals Inc makes up approx 0.20% of Blackrock Fund Advisors’s portfolio.Swiss National Bank boosted its stake in REGN in the latest quarter, The investment management firm added 17,300 additional shares and now holds a total of 216,400 shares of Regeneron Pharmaceuticals Inc which is valued at $95,512,468. Regeneron Pharmaceuticals Inc makes up approx 0.15% of Swiss National Bank’s portfolio.Ibm Retirement Fund reduced its stake in REGN by selling 32 shares or 0.31% in the most recent quarter. The Hedge Fund company now holds 10,159 shares of REGN which is valued at $3,975,623. Regeneron Pharmaceuticals Inc makes up approx 0.14% of Ibm Retirement Fund’s portfolio.
Regeneron Pharmaceuticals Inc opened for trading at $420.15 and hit $424.999 on the upside on Tuesday, eventually ending the session at $420.61, with a gain of 0.47% or 1.96 points. The heightened volatility saw the trading volume jump to 4,52,160 shares. Company has a market cap of $44,288 M.
On the company’s financial health, Regeneron Pharmaceuticals Inc reported $2.82 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $2.65. The company had revenue of $1213.00 million for the quarter, compared to analysts expectations of $1237.52 million. The company’s revenue was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.89 EPS.
Many Wall Street Analysts have commented on Regeneron Pharmaceuticals Inc. Shares were Downgraded by Robert W. Baird on Aug 5, 2016 to ” Neutral” and Lowered the Price Target to $ 448 from a previous price target of $505 .Regeneron Pharmaceuticals Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016.
Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.